Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Genetron Health Targeting Liquid Biopsy, Early Cancer Detection for Future Business Growth

Genetron Health Targeting Liquid Biopsy, Early Cancer Detection for Future Business Growth

Nov 10, 2020
|
Molika Ashford
Premium

NEW YORK – Although most of the clinical testing and biopharma services Genetron Health currently provides are in the area of advanced cancer genotyping, the firm said this week that its eye is firmly on liquid biopsy testing, especially for early cancer detection and monitoring, as it maps out future technology and commercial development plans for both China and the US.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Open Spot

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 

US to Remain in WHO

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

Dip Possible

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

Nature Papers Examine Australian Lungfish Genome, Essential E. Coli Genes

In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
17
Featured Webinar

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Sponsored by
BioLegend

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Molecular Diagnostics

  1. Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents

  2. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

  3. CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

  4. Lucira Health Files for $115M IPO

  5. Invitae to Raise $400M in Proposed Public Offering

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.